Paradigm Biopharmaceuticals Ltd. (AU:PAR) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Paradigm Biopharmaceuticals Ltd. has issued 40 million fully paid ordinary shares without disclosure under the Corporations Act, affirming compliance with all relevant regulations. The Melbourne-based company is focused on advancing its late-stage drug developments, particularly its injectable treatment for diseases like osteoarthritis and mucopolysaccharidosis.
For further insights into AU:PAR stock, check out TipRanks’ Stock Analysis page.